Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CTH | P32929 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794397 | 0.82 | IDO1 (1.00) | IDO1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL2930645 | 0.81 | SMN1; SMN2 (0.73) | IDO1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL2930725 | 0.81 | IDO1 (0.72) | IDO1SMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL2932575 | 0.79 | IDO1 (0.70) | IDO1SMN1; SMN2RAB9AALDH1A1KMT2A | |
| SCHEMBL2792097 | 0.79 | IDO1 (0.70) | IDO1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL2930785 | 0.77 | LMNA (0.66) | IDO1SMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL525331 | 0.77 | IDO1 (0.62) | IDO1SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL424305 | 0.73 | KDM4E (0.65) | SMN1; SMN2HTTRAB9ANPC1KDM4E | |
| SCHEMBL424304 | 0.73 | HDAC2 (0.58) | SMN1; SMN2HTTRAB9ANPC1KDM4E | |
| SCHEMBL10566671 | 0.72 | IDO1 (0.81) | IDO1SMN1; SMN2HTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885SMN1; SMN2 4672/4885HTT 3243/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885SMN1; SMN2 4556/4885HTT 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.